• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Clever Leaves Appoints George Schultze to Board of Directors

    2/2/22 4:05:00 PM ET
    $CLVR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVR alert in real time by email

    BOCA RATON, Fla., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, today appointed George Schultze to its Board of Directors. Mr. Schultze was also appointed to the Board's Audit Committee.

    Mr. Schultze is the founder and managing member of Schultze Asset Management, L.P. ("SAM"), where he chairs the firm's investment and strategy committees. With over 25 years of experience in the investment industry, he is widely recognized as an expert on event-driven and special situations investing. Before founding SAM, Mr. Schultze held various roles at MD Sass, Fiduciary Partners fund of funds, the Mayer Brown & Platt law firm, and Merrill Lynch. He received his BA in Economics and Political Science from Rutgers College and is a joint graduate of Columbia Business School and Columbia Law School, JD/MBA. Since founding SAM in 1998, Mr. Schultze has served on over 35 boards of directors and various committees.

    "As we work to continue executing on our growth objectives, we are pleased to welcome George to our Board of Directors," said Kyle Detwiler, Chairman and CEO of Clever Leaves. "We are grateful for the support George and the SAM team have provided us as shareholders throughout our first year as a public company. We view the one-year lock-up and George's partnership as a board member as strong endorsements of Clever Leaves' capabilities and long-term vision. We look forward to leveraging his expertise to further activate our commercial pipeline and enhance shareholder value."

    Commenting on his appointment, Mr. Schultze said: "Clever Leaves has entered 2022 with a robust operational footprint and strong positioning across several key emerging global cannabis markets. Having not sold a single share since the public listing of Clever Leaves, entering into a one-year lockup is our signal of confidence in the Company's vision and commercial prospects as well as an indication of our belief that the current share price does not reflect the potential value of the Company's unique position in the cannabis industry. I look forward to collaborating with the Board and management team to maximize value for all shareholders."

    Lock-Up Agreement and Waiver of Certain Rights, Including Warrant Exercise

    On February 2, 2022, Schultze Special Purpose Acquisition Sponsor, LLC (the "Holder") entered into a Waiver of Certain Rights (the "Waiver") with Clever Leaves, wherein the Holder has agreed that it will not offer, sell, contract to sell, pledge or otherwise dispose, directly or indirectly, of any of its approximately 2.3 million Clever Leaves common shares beneficially owned, representing approximately 8% of the common shares outstanding, its 4.9 million warrants, representing approximately 28% of the warrants outstanding, or any securities that may be converted into, exercisable, or exchangeable for common shares without prior written consent of the Board until one year following the date of the Waiver. The Holder has also waived its right to exercise any of its warrants, a waiver which will terminate upon 61 days' prior written notice to the Company. In addition, the Holder has waived its right to nominate a director to the Board, pursuant to the Investors' Rights Agreement dated December 18, 2020, until the earlier of when Schultze is no longer a member of the Board's Audit Committee or when he ceases to be eligible to be a member of the Audit Committee under Nasdaq's rules and regulations.

    More information about the appointment can be found on the Form 8-K filed with the Securities and Exchange Commission on February 2, 2022.

    About Clever Leaves Holdings Inc.

    Clever Leaves is a multinational cannabis company with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade cannabinoid processing as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry's leading global cannabis companies recognized for its principles, people, and performance while fostering a healthier global community. Clever Leaves has received multiple international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including European Union Good Manufacturing Practices (EU GMP) Certification, a Good Manufacturing Practices (GMP) Certification by Colombia National Food and Drug Surveillance Institute - Invima, and Good Agricultural and Collecting Practices (GACP) Certification. Clever Leaves was granted a license in Portugal from Infarmed – the Portuguese health authority – which allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes. In addition, the Portuguese operation was also granted by Control Union Certifications to be compliant with GACP and GAP from EMEA and WHO, as well as with CUMCS – G.A.P.

    For more information, visit https://cleverleaves.com/en/home/ and follow Clever Leaves on Twitter and LinkedIn.

    Forward-Looking Statements

    This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "evolve," "expect," "forecast," "future," "guidance," "intend," "may," "opportunity," "outlook," "pipeline," "plan," "predict," "potential," "projected," "seek," "seem," "should," "will," "would" and similar expressions (or the negative versions of such words or expressions) that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements as well as our outlook for 2021 are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Important factors that may affect actual results or the achievability of the Company's expectations include, but are not limited to: (i) expectations with respect to future operating and financial performance and growth, including if or when Clever Leaves will become profitable; (ii) Clever Leaves' ability to execute its business plans and strategy and to receive regulatory approvals; (iii) Clever Leaves' ability to capitalize on expected market opportunities, including the timing and extent to which cannabis is legalized in various jurisdictions; (iv) global economic and business conditions; (v) geopolitical events, natural disasters, acts of God and pandemics, including the economic and operational disruptions and other effects of COVID-19 such as the global supply chain crisis, travel restrictions, delays or disruptions to physical shipments (including outright bans on imported products), delays in issuing licenses and permits, delays in hiring necessary personnel to carry out sales, cultivation and other tasks, and financial pressures upon Clever Leaves and its customers; (vi) regulatory developments in key markets for the company's products, including international regulatory agency coordination and increased quality standards imposed by certain health regulatory agencies, and failure to otherwise comply with laws and regulations; (vii) uncertainty with respect to the requirements applicable to certain cannabis products as well as the permissibility of sample shipments, and other risks and uncertainties; (viii) consumer, legislative, and regulatory sentiment or perception regarding Clever Leaves' products; (ix) lack of regulatory approval and market acceptance of Clever Leaves' new products; (x) the extent to which Clever Leaves' is able to monetize its existing THC market quota within Colombia; (xi) demand for Clever Leaves' products and Clever Leaves' ability to meet demand for its products and negotiate agreements with existing and new customers; (xii) developing product enhancements and formulations with commercial value and appeal; (xiii) product liability claims exposure; (xiv) lack of a history and experience operating a business on a large scale and across multiple jurisdictions; (xv) limited experience operating as a public company; (xvi) changes in currency exchange rates and interest rates; (xvii) weather and agricultural conditions and their impact on the Company's cultivation and construction plans, (xviii) Clever Leaves' ability to hire and retain skilled personnel in the jurisdictions where it operates; (xix) Clever Leaves' rapid growth, including growth in personnel; (xx) Clever Leaves' ability to remediate a material weakness in its internal control cover financial reporting and to develop and maintain effective internal and disclosure controls; (xxi) potential litigation; (xxiii) access to additional financing; and (xxiv) completion of construction initiatives on time and on budget. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in Clever Leaves' most recent filings with the SEC. All subsequent written and oral forward-looking statements concerning Clever Leaves and attributable to Clever Leaves or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Clever Leaves expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    Clever Leaves Investor Inquiries:

    Cody Slach or Jackie Keshner

    Gateway Investor Relations

    +1-949-574-3860

    [email protected]

    Clever Leaves Press Contacts:

    McKenna Miller

    KCSA Strategic Communications

    +1-347-487-6197

    [email protected]

    Diana Sigüenza

    Strategic Communications Director

    +57-310-236-8830

    [email protected]

    Clever Leaves Commercial Inquiries:

    Andrew Miller

    Vice President Sales - EMEA, North America, and Asia-Pacific

    +1-416-817-1336

    [email protected]



    Primary Logo

    Get the next $CLVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVR

    DatePrice TargetRatingAnalyst
    12/23/2021$12.00 → $10.00Buy
    Canaccord Genuity
    11/12/2021$13.00 → $12.00Buy
    Canaccord Genuity
    7/27/2021$13.00Buy
    Canaccord Genuity
    7/23/2021Market Perform
    Cowen
    More analyst ratings

    $CLVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Bcm Investimentos Fundo De Investimento Multimercado Credito Privado Investimento No Exterior claimed ownership of 322,234 shares (SEC Form 3)

      3 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      5/21/24 8:07:09 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hague Henry R Iii sold $563 worth of shares (170 units at $3.31), decreasing direct ownership by 1% to 11,951 units (SEC Form 4)

      4 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      3/12/24 4:50:10 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hague Henry R Iii sold $1,623 worth of shares (411 units at $3.95), decreasing direct ownership by 3% to 12,121 units (SEC Form 4)

      4 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      2/29/24 4:01:46 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Leadership Updates

    Live Leadership Updates

    See more
    • Clever Leaves Reminds Shareholders of its Upcoming Annual Meeting on June 2, 2023

      TOCANCIPÁ, Colombia, May 26, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, reminds shareholders that it will hold its 2023 Annual Meeting of Shareholders (the "Annual Meeting") on Friday, June 2, 2023 at 10:00 a.m. Eastern Time. The Annual Meeting will be in a virtual-only format. Clever Leaves reminds investors that its board has recommended that shareholders vote "FOR" the proposal to elect each of the five (5) nominees named in the proxy statement to the Board of Directors, "FOR" the appointment of Marcum LLP as the Company's independent registered public accounting firm to serve as in

      5/26/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Appoints William Muecke to Board of Directors

      BOCA RATON, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced that it has appointed William Muecke to its board of directors, effective March 25, 2022, to fill the vacancy resulting from the previously announced departure of Kyle Detwiler, the Company's current chairman and CEO, effective March 24, 2022. Muecke was also appointed to the board's nominating and governance committee, as well as its compensation committee. Muecke is a co-founder and managing member of Artemis Growth Partners, an impact-focused ESG

      3/17/22 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Announces Leadership Transition Plan

      BOCA RATON, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, today announced a leadership transition plan. Andres Fajardo, currently a director and president of the Company, has been selected to succeed Kyle Detwiler as CEO, effective March 24, 2022. Detwiler will remain CEO until March 24, 2022, to ensure a smooth transition, and he will continue to serve as the Company's Chairman until such date. "Today's leadership changes are the culmination of a succession planning process that our board and Kyle have worked on tog

      2/9/22 7:59:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Financials

    Live finance-specific insights

    See more
    • Clever Leaves Reports Third Quarter 2023 Results

      - Q3 Revenue Increased 33% Year-Over-Year, Propelled by 135% Year-Over-Year Growth in Cannabinoid Revenue, Along with 6% Year-Over-Year Growth in Non-Cannabinoid Revenue - - Q3 Adjusted EBITDA Improved Year-Over-Year to $(2.6) Million Compared to $(3.7) Million, Reflecting Revenue Growth and Continued Aggressive Expense Reductions - - Cash Balance at October 31, 2023 was $6.2 Million, with $1.9 Million in Subsequent Capital Received from the November Sale of the Company's Remaining Stake in Cansativa - - Updated Full Year 2023 Guidance Reflects Revenue Timing Shifts, Revenue Mix, and Adjusted EBITDA Improvement from Continued Operating Efficiencies - TOCANCIPÁ, C

      11/9/23 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves to Hold Third Quarter 2023 Conference Call on Thursday, November 9, 2023 at 5:00 p.m. ET

      TOCANCIPÁ, Colombia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, will hold a conference call on Thursday, November 9, 2023 at 5:00 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023. The Company will provide its financial results in a press release prior to the conference call. Clever Leaves management will host the conference call, followed by a question-and-answer session. Conference Call Date: Thursday, November 9, 2023Time: 5:00 p.m. Eastern timeToll-free dial-in number: 1-855-238-2333International dial-in number: 1-412-317-5222Confere

      11/2/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Reports Second Quarter 2023 Results

      - Total Revenue Increased 21% Year-Over-Year, Driven by 151% Year-Over-Year Growth in Cannabinoid Revenue - - Continued Expense Reductions Drive Improved Adjusted EBITDA Performance of ($2.1) Million - - July 2023 Sale of Portuguese Processing Assets Added $2.7 Million in Cash Following the End of Q2 - - Reaffirming Previously Announced 2023 Guidance - TOCANCIPÁ, Colombia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, is reporting financial and operating results for the second quarter ended June 30, 2023. All financial information is provided in US dollars unless otherwise in

      8/14/23 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clever Leaves Announces Voluntary Delisting and SEC Deregistration

      TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, today announced that its Board of Directors (the "Board") determined to voluntarily delist its common shares, without par value (the "common shares") and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the "Warrants" and together with the common shares, the "Securities") from The Nasdaq Stock Market LLC ("Nasdaq") and deregister its Securities in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"

      4/26/24 4:10:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Reports Fourth Quarter and Full Year 2023 Results

      - 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023. All financial information is provided in US doll

      4/1/24 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia

      TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds ("Paradise"), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for cultivation across Colombia and Latin America. The two companies have already begun rigorous selection, phenotyping, and agronomic trials of several Paradise varieties at Clever Leaves'

      2/13/24 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Clever Leaves Holdings Inc.

      15-12G - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/16/24 4:45:21 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Clever Leaves Holdings Inc.

      EFFECT - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/9/24 12:15:20 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clever Leaves Holdings Inc.

      S-8 POS - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/6/24 4:15:58 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13D/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/21/24 8:03:23 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Clever Leaves Holdings Inc.

      SC 13D - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/15/24 9:11:49 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13G/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      1/23/24 9:07:27 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      12/23/21 7:40:56 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      11/12/21 8:49:58 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity initiated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $13.00

      7/27/21 7:11:17 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care